Barclays Maintains Overweight on Monopar Therapeutics, Raises Price Target to $145

Benzinga · 2d ago
Barclays analyst Etzer Darout maintains Monopar Therapeutics (NASDAQ:MNPR) with a Overweight and raises the price target from $128 to $145.